All articles by Molly Lempriere
Molly Lempriere
Betting big on Gamma Delta T Cells
A novel development platform being developed by a British biotech could lead to new treatments for cancer and auto-inflammatory diseases. Elly Earls finds out why drug giant Takeda is betting big on its potential.
Reforming paediatric cancer trials in Europe
Outdated European regulations are depriving children of access to the latest cancer treatments. Elly Earls asks the ICR’s Dr Eva Sharpe why now is the time for reform and how the rules need to change.
Could a temperature-resistant vaccine spell the end for rabies and yellow fever?
Current vaccines for rabies and yellow fever are plagued by the difficulties of transporting temperature-controlled drugs. A new European consortium led by KU Leuven may have the solution. Elly Earls reports.
Cancergraph: a desperately needed link between patient and clinical trial
While many cancer patients are interested in clinical trials, tough eligibility criteria and a lack of information mean only a fraction actually participate. Help may be at hand, however, thanks to a new mobile app called Cancergraph, thatwhich can match patients with trials that apply to them. Abi Millar speaks to the developers to find out more.
Medicines Discovery Catapult: improving collaborative drug discovery in the UK
The Medicines Discovery Catapult, one of 11 technology and innovation centres established by Innovate UK, has been set up to enable new, collaborative means of drug discovery. Abi Millar spoke to CEO Chris Molloy to find out more.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Why the UK NHS needs clinical research
New data published by the UK’s National Institute for Health Research has revealed that for the first time ever, all NHS Trusts in England are engaged in clinical research. Abi Millar finds out why, at such a testing time for the NHS, a strong clinical research focus is absolutely critical for a strong health service.
Pay-for-delay: how far will companies go to protect market exclusivity?
While some form of patent protection is clearly necessary, pay-for-delay agreements are more contentious. What happens when pharma companies pay large sums to prolong a patent and delay exposure to competition? Do patients suffer? Abi Millar investigates.
Genomic array could unlock war against diseases in Africa
A new genomic array will provide the foundation for more detailed research than ever before into the genetic and environmental causes of common diseases in Africa. Elly Earls finds out from two of the project’s key players how their affordable innovation could improve the health of a continent.
Developing new drugs for Tourette syndrome
Tourette syndrome is a complex condition, and unscrambling the neurological factors behind the disorder has been a major factor for those working on treatments. But researchers are coming ever closer to understanding its puzzling etiology and are developing new drugs to suit. Abi Millar explores.